ACHV — Achieve Life Sciences, Inc.
$6.49-0.15%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ACHV in the TickerWise workspace.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 25
- Website: https://www.achievelifesciences.com
Latest SEC filings for ACHV
Latest ACHV news
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications Read article
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards Read article
- Achieve Life Sciences appoints Benjamin Halladay as CFO Read article
- Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer Read article
- Achieve a new Buy at Stifel on potential of smoking cessation drug cytisinicline Read article
- Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.